Non-Hodgkin Lymphoma (NHL) Market Analysis, Growth, Trend, Insights, Epidemiology and Forecast-2023

Researchmoz added Most up-to-date research on "Non-Hodgkin Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023" to its huge collection of research reports.

DelveInsights Non-Hodgkin Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023-7MM Reports provides an overview of the disease and global market size of the Non-Hodgkin Lymphoma for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the diagnosed cases of Non-Hodgkin Lymphoma from 2012-2023.

Non-Hodgkin Lymphoma is the most common lymphoma which affects large number of people. It begins in lymphocytes present in lymph nodes of body parts such as neck or chest or under the arms. It widely spreads to the other lymph nodes and to other organs such as bone marrow, lungs, or liver.

According to DelveInsight, the market size for Non-Hodgkin Lymphoma of 7 MM is estimated to be USD XX Million by 2023 at a CAGR of 8% for the forecast period i.e., 2012-2023.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope

The report will help in developing business strategies by understanding the trends shaping and driving the Non-Hodgkin Lymphoma market.

Organize sales and marketing efforts by identifying the best opportunities for Non-Hodgkin Lymphoma in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.

To understand the future market competition in the 7MM market of Non-Hodgkin Lymphoma and Insightful review of the key market drivers and barriers.

To understand the regulatory scenario in major markets.

The Report also covers the detailed historical and forecasted Non-Hodgkin Lymphoma market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2012-2023.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1065650

Table Of Content

Report Introduction
Non-Hodgkin Lymphoma Market Overview at a Glance
Global Market Size of Non-Hodgkin Lymphoma (2012-2023)
7 MM Market Size of Non-Hodgkin Lymphoma (2012-2023)
Total Market Share Distribution of Non-Hodgkin Lymphoma for 7 MM in 2016
Total Market Share Distribution of Non-Hodgkin Lymphoma for 7 MM in 2023
Non-Hodgkin Lymphoma (NHL)
Overview
Types of Non-Hodgkin Lymphoma
Stages of Non-Hodgkin Lymphoma
Pathophysiology
Etiology
Risk Factors
Diagnosis
Treatment
Epidemiology and Patient Population
Total number of cases 7MM Countries (2016 & 2023)
United States
Diagnosed Cases of Non-Hodgkin Lymphoma in United States
Germany
Diagnosed Cases of Non-Hodgkin Lymphoma in Germany
France
Diagnosed Cases of Non-Hodgkin Lymphoma in France
United Kingdom
Diagnosed Cases of Non-Hodgkin Lymphoma in United Kingdom
Spain
Diagnosed Cases of Non-Hodgkin Lymphoma in Spain
Italy
Diagnosed Cases of Non-Hodgkin Lymphoma in Italy
Japan
Diagnosed Cases of Non-Hodgkin Lymphoma in Japan
Treatment Algorithm
Current Unmet Needs
Marketed Drugs
Rituxan (MabThera)
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Efficacy
Safety
Side effects
Other marketed Products for Subtypes of NHL
Emerging Therapies
Copanlisib: Bayer AG
Product Development Activities
Clinical Development
Product Profile
Clinical Trial by Phase
Ibrutinib: Janssen Biotech, Inc
Product Development Activities
Clinical Development
Product Profile
Clinical Trial by Phase
Pixantrone: CTI BioPharma Corp.
Product Development Activities
Clinical Development
Product Profile
Clinical Trial by Phase
Other Emerging Therapies for Subtypes of NHL
Global Non-Hodgkin Lymphoma: Country-Wise Market Analysis
Overview on Total Non-Hodgkin Lymphoma Market (2016)
Overview on Total Non-Hodgkin Lymphoma Market (2023)
United States Market Size
Non-Hodgkin Lymphoma (NHL) Distribution Based on Types and Sub Types (2016)
Europe Market Size
Germany Market Size
Non-Hodgkin Lymphoma (NHL) Distribution Based on Types and Sub Types (2016)
France Market Size
Non-Hodgkin Lymphoma (NHL) Distribution Based on Types and Sub Types (2016)
United Kingdom Market Size
Non-Hodgkin Lymphoma (NHL) Distribution Based on Types and Sub Types (2016)
Spain Market Size
Non-Hodgkin Lymphoma (NHL) Distribution Based on Types and Sub Types (2016)
Italy Market Size
Non-Hodgkin Lymphoma (NHL) Distribution Based on Types and Sub Types (2016)
Japan Market Size
Non-Hodgkin Lymphoma (NHL) Distribution Based on Types and Sub Types (2016)
Market Drivers
Market Barriers
Report Methodology
Consulting Services

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1065650

Non-Hodgkin Lymphoma Innovative Licensing Industry Opportunities Key Trends, Size, Growth, Shares And Forecast Research Report

Researchmoz added Most up-to-date research on "Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma" to its huge collection of research reports.

Non-Hodgkin Lymphoma (NHL) can be seen as a collection of up to 60 smaller subtypes of malignant lymphoid disease, defined by distinct morphological, cytogenetic and immunophenotypic characteristics that can be broadly classified as either indolent or aggressive disease. The slow growing nature of the former means that first-line treatment for diagnosed patients can be delayed, an option not commonly recommended for aggressive disease. Across both indolent and aggressive disease, first-line chemotherapy in combination with the blockbuster drug rituxumab can induce high rates of response, and prolonged durations of remission. Despite this, indolent disease is typically incurable, with the most aggressive lymphoma subtype - diffuse large B-cell lymphoma having 5-year survival rates of ~50%. Re-treatment with chemotherapy can induce second and subsequent remissions, but most NHL patients develop chemotherapy resistant disease, for whom there are limited treatment options. Overall, in terms of numbers small molecule chemotherapeutic agents dominate the current market, with a clear need for novel targeted therapies to prolong durations of remission, and provide options for patients with chemo resistant, heavily pretreated disease.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=373016

The current developmental pipeline addresses these gaps in the market, dominated by cancer immunotherapies and inhibitors of cancer-associated signal transduction. Pathways of significant interest include B-cell receptor signaling, the PI3K/Akt/mTOR pathway, and Wnt/ß-catenin signaling, as well as oncogenes such as BCL-6 and BCL-2. Characteristic cell surface molecules that represent targets for cancer immunotherapies include CD19, LMP-1/2 and CD20, with several pipeline drugs already approved for CD20. First-in-class drug development in NHL corresponds strongly to these known somatic mutations and affected pathways. Clinical results of drugs against profiled targets in this report show many are being investigated in relapsed disease.

Scope

There are 666 marketed products for NHL, 95% of which are small molecules -

- What are the dominant mechanisms of action across marketed products?

The treatment of lymphoma is dominated by the use of combination cyclophosphamide based chemotherapy in combination with rituximab -

- What are these chemotherapy regimens?
- How did they perform in key clinical trials?

The variation in molecule type has shifted away from small molecules, whose dominance has decreased to 46% across the pipeline -

- What are the dynamics of the remaining 54% of the pipeline?
- How does this reflect the need for novel targeted therapies?

There is a significant shift away from cytotoxic agents, with the current pipeline dominated by cancer immunotherapies and signal transduction inhibitors -

- What is the scientific rationale behind these mechanisms of action?
- How successful have approved targeted therapies been?

Profiled first-in-class therapies include: PIK3CA, EZH2, CD40 and MDM2 -

- What is the scientific rationale behind these targets?
- What preclinical and clinical results are available for drugs against these targets?
- What is the overall opinion on these targets for drug development across NHL?

Reasons to buy

This report will allow you to -

- Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
- Visualize the composition of the NHL market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the NHL pipeline, and stratify by stage of development, molecule type and molecular target. There are promising signs in focussed on the development of targeted therapies for this disease.
- Visualize the clinical safety and efficacy of drugs against first-in-class targets via a detailed heat map, outlining the results across major clinical trial endpoints.
- Identify commercial opportunities in the NHL deals landscape by analyzing trends in licensing and co-development deals, and those first-in-class drugs which are yet to be involved in a strategic alliance.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=373016